HilleVax (NASDAQ:HLVX) Given “Neutral” Rating at HC Wainwright

HilleVax (NASDAQ:HLVX)‘s stock had its “neutral” rating reaffirmed by stock analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They currently have a $2.00 target price on the stock. HC Wainwright’s target price suggests a potential upside of 25.79% from the stock’s previous close.

HilleVax Stock Down 1.2 %

Shares of HilleVax stock opened at $1.59 on Monday. The company has a market capitalization of $79.19 million, a price-to-earnings ratio of -0.51 and a beta of 0.76. The stock’s 50-day simple moving average is $1.82 and its 200-day simple moving average is $1.86. HilleVax has a 52 week low of $1.55 and a 52 week high of $16.66.

HilleVax (NASDAQ:HLVX) last announced its quarterly earnings data on Friday, March 28th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.02). On average, equities analysts expect that HilleVax will post -2.64 earnings per share for the current year.

Hedge Funds Weigh In On HilleVax

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Takeda Pharmaceutical Co. Ltd. purchased a new stake in shares of HilleVax during the 4th quarter worth approximately $13,919,000. Lightspeed Management Company L.L.C. bought a new stake in HilleVax in the fourth quarter worth $4,847,000. Deutsche Bank AG raised its stake in HilleVax by 32.9% during the fourth quarter. Deutsche Bank AG now owns 420,550 shares of the company’s stock valued at $871,000 after purchasing an additional 104,001 shares in the last quarter. Millennium Management LLC lifted its position in HilleVax by 59.6% during the fourth quarter. Millennium Management LLC now owns 411,820 shares of the company’s stock valued at $852,000 after purchasing an additional 153,815 shares during the last quarter. Finally, Northern Trust Corp grew its stake in shares of HilleVax by 2.8% in the 4th quarter. Northern Trust Corp now owns 249,610 shares of the company’s stock worth $517,000 after buying an additional 6,916 shares in the last quarter. 86.42% of the stock is owned by institutional investors.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.